title: Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms.
abstract: Enalapril maleate (EM) is a widely used anti-hypertensive drug which is unstable when mixed with excipients. Enalaprilate and diketopiperazine (DPK) are the main degradation products of enalapril. The in situ preparation of enalapril sodium salt (NaE) has been used to improve drug stability in dosage forms; however, gas release and product rejection ensue when the chemical reaction for obtaining the sodium salt is not completely finished before packaging. This study evaluated the effect of stearic acid (SA) on enalapril stability in microcrystalline cellulose (MCC) pellets containing EM or NaE. MCC pellets containing SA were prepared by the extrusion-spheronization technique and characterized. Enalapril stability and dissolution were then evaluated. DPK and enalaprilate formation were reduced by the addition of SA in pellets containing EM. The overall enalapril degradation in these formulations was lower when compared with pellets containing EM or even NaE prepared without SA. The immediate-release characteristic was maintained by the addition of 5% crospovidone to all the formulations tested. The incorporation of SA into NaE pellets resulted in unexpected enalapril degradation, caused by the interaction of these compounds, as suggested by a thermal analysis of the SA-NaE binary mixture. The findings presented here showed that formulations containing SA could substitute the formation of NaE, since they provide better enalapril stability in solid dosage forms. In addition, it is suggested that the stabilization effects would be observed for other N-carboxyalkyl dipeptide analogs with angiotensin converting enzyme inhibition activity, since these new entities share the same degradation pathway of enalapril.
authors.affiliation: Laboratory of Pharmaceutical Technology, Federal University of Goiás, Goiânia, GO, Brazil.
authors.forename: Talita A
authors.initials: TA
authors.lastname: Cunha
authors.forename: Raphael C
authors.initials: RC
authors.lastname: Serpa
authors.forename: Ana Paula M
authors.initials: AP
authors.lastname: de Oliveira
authors.forename: Letícia N
authors.initials: LN
authors.lastname: Nasser
authors.forename: Luis Alexandre P
authors.initials: LA
authors.lastname: de Freitas
authors.forename: Stephania F
authors.initials: SF
authors.lastname: Taveira
authors.forename: Danielle G A
authors.initials: DG
authors.lastname: Diniz
authors.forename: Eliana M
authors.initials: EM
authors.lastname: Lima
authors.forename: Ricardo N
authors.initials: RN
authors.lastname: Marreto
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry*; D004304:Dosage Forms; D004355:Drug Stability; D004656:Enalapril / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D012995:Solubility; D013229:Stearic Acids / Q000737:chemistry*; D013818:Thermogravimetry
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004304:Dosage Forms; D013229:Stearic Acids; C031183:stearic acid; D004656:Enalapril
references.citation: J Pharm Biomed Anal. 2001 Jul;25(5-6):893-902
references.pmid: 11377072
references.citation: J Pharm Biomed Anal. 2008 Aug 5;47(4-5):934-7
references.pmid: 18472382
references.citation: Eur J Pharm Biopharm. 2009 Jan;71(1):38-46
references.pmid: 18771727
references.citation: Int J Pharm. 2009 Oct 20;381(1):56-61
references.pmid: 19486933